Long-term effectiveness and safety of Canakinumab in patients with TRAPS: analysis of the RELIANCE non-interventional study
Introduction: This is an interim analysis of the long-term effectiveness and safety of canakinumab in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) cohort of the RELIANCE non-interventional study. Methods: From June 2018, the RELIANCE non-interventional study enrolled paedi...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2026
|
| In: |
Rheumatology and therapy
Year: 2026, Volume: 13, Issue: 1, Pages: 135-155 |
| ISSN: | 2198-6584 |
| DOI: | 10.1007/s40744-025-00809-y |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s40744-025-00809-y
|
| Author Notes: | Norbert Blank, Catharina Schuetz, Markus Hufnagel, Gerd Horneff, Michael Borte, Tilmann Kallinich, Prasad T. Oommen, Ales Janda, Joerg Henes, Julia Weber-Arden, Michael Stock, Jasmin B. Kuemmerle-Deschner |
| Summary: | Introduction: This is an interim analysis of the long-term effectiveness and safety of canakinumab in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) cohort of the RELIANCE non-interventional study. Methods: From June 2018, the RELIANCE non-interventional study enrolled paediatric (aged ≥ 2 – < 18 years) and adult patients (aged ≥ 18 years) with TRAPS who were receiving canakinumab as part of their routine medical care. Physician- and patient-reported measures of disease activity, dosing patterns and safety were evaluated at baseline and every 6 months until the end-of-study visit.Results: A total of 21 patients with TRAPS were enrolled by the analysis cut-off date of December 2022, of which 61.9% (13/21) were paediatric patients (< 18 years) and 66.7% (14/21) were female. All patients were pre-treated with canakinumab prior to enrolment (median duration of canakinumab treatment prior to study inclusion: 1.2 years). Disease activity, evaluated by physician-reported (physician’s global assessment, disease remission, C-reactive protein, serum amyloid A) and patient-reported (disease activity, fatigue, impact on social life, autoinflammatory disease activity index diary) measures, was generally well controlled throughout the study. At baseline, the majority of patients (71.4%) were receiving the recommended starting dose (SD) of canakinumab, with a more even distribution between the < SD, SD, and > SD dosing schedules observed from month 6. No serious adverse drug reactions were reported. Patients continued to receive vaccinations during long-term treatment with canakinumab. In total, 85.7% (18/21) of patients met the Eurofever/PRINTO classification criteria for TRAPS, 42.9% (9/21) with the presence of a confirmative TNFRSF1A genotype and 42.9% (9/21) without. In total, 14.3% (3/21) of patients did not meet the classification criteria.Conclusions: Data from this interim analysis support the long-term effectiveness and safety of canakinumab for the treatment of TRAPS. |
|---|---|
| Item Description: | Online veröffentlicht: 26. November 2025 Gesehen am 29.01.2026 |
| Physical Description: | Online Resource |
| ISSN: | 2198-6584 |
| DOI: | 10.1007/s40744-025-00809-y |